Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 4, 2017 (9 years ago)

Quillivant XR methylphenidate HCl

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted, Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.

Affected NDC 24478-0200-20

Compare with the code on your package — it is the most precise check available.

Drug: Methylphenidate

Recalling firm
Pfizer Inc.
NDC code
24478-200-20
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1163-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Methylphenidate recalls

See all
Class II · Moderate risk

Methylphenidate Hydrochloride

Failed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications.

Terminated Dissolution failure Trigen Laboratories NDC 13811-708-10 D-0579-2024

Other recalls by Pfizer Inc.

All 2017 recalls